Actavis Inks $1.1M Deal In ADHD Medication Antitrust Suit
A proposed class of parents and caregivers who've accused Actavis of violating antitrust laws by delaying alternatives to its attention deficit hyperactivity disorder medication Intuniv have asked a Massachusetts federal judge...To view the full article, register now.
Already a subscriber? Click here to view full article